Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)

Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)

Article information

The original article contained incorrect terminology for one of the cardiac measures; throughout the manuscript and supplementary information ‘intraventricular septum wall thickness’ should have been given as ‘interventricular septum wall thickness’. Corrections should also be noted for Tables 1 and 4: in the Table 1 legend ‘Low risk – Neither above at baseline’ should read ‘Low risk – Neither above threshold at baseline’; in Table 4, the rows ‘Mild: eGFR > 60 to < 90 ml/min/1.73 m²’ and ‘Moderate: eGFR > 30 to < 60 ml/min/1.73 m²’ should read ‘Mild: eGFR ≥ 60 to < 90 ml/min/1.73 m²’ and ‘Moderate: eGFR ≥ 30 to < 60 ml/min/1.73 m²’, respectively. The original article also contained a mistake in the text of the Pharmacokinetics sub-section of Results; ‘There were no apparent differences in revusiran C_max between patients with mild (eGFR: 30 and < 60 ml/min/1.73 m²) or moderate (eGFR: 60 to < 90 ml/min/1.73 m²) renal impairment when compared with patients with normal (eGFR: ≥ 90 ml/min/1.73 m²) renal function at Weeks 0, 26, and 52 (p > 0.20) (Supplementary Fig. 6)’ should read ‘There were no apparent differences in revusiran C_max between patients with mild (eGFR: ≥ 60 to < 90 ml/min/1.73 m²) or moderate (eGFR: ≥ 30 and < 60 ml/min/1.73 m²) renal impairment when compared with patients with normal (eGFR: ≥ 90 ml/min/1.73 m²) renal function at Weeks 0, 26, and 52 (p > 0.20) (Supplementary Fig. 6)’.

Cardiovasc Drugs Ther. 2020 Feb 15

Published online 2020 Feb 15. doi: https://doi.org/10.1007/s10557-019-06919-4

PMID: 32062791

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

This corrects the article “Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)” in Cardiovasc Drugs Ther, published Online First on 15th February 2020.